Business Context and Reporting Period
This Form 8-K was filed by Cactus Ventures, Inc. on March 1, 2013. The filing reports a corporate governance event: the appointment of an interim Chief Executive Officer. Note: The request metadata references "Actinium Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Cactus Ventures, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Sergio Traversa as Interim President and Chief Executive Officer, effective March 1, 2013. Dr. Traversa, who has served as a Director since August 2012, was unanimously approved by the Board. The Board is actively seeking a permanent candidate for the CEO position.
Guidance, Outlook, and Risks
- Management Commentary: The Board is actively looking for a candidate to fill the permanent Chief Executive Officer position.
- Compensation: No employment agreement has been entered into with the newly appointed interim CEO at this time.
- Related Party Transactions: There are no reportable related party transactions under Item 5.02 or Item 404(a) of Regulation S-K.
- Risks/Contingencies: No specific risks or contingencies are detailed in this filing beyond the interim nature of the leadership appointment.
Investor Verification Checklist
- Verify the correct registrant name (Cactus Ventures, Inc. vs. Actinium Pharmaceuticals, Inc.) to ensure data relevance.
- Confirm the status of the search for a permanent CEO and any subsequent filings regarding that appointment.
- Review future filings for the execution of a formal employment agreement and compensation terms for the interim CEO.
- Check for any financial disclosures in subsequent 10-K or 10-Q filings, as this 8-K contains no financial data.